# Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma

> **NCT00433537** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 77 (actual)

## Conditions studied

- Contiguous Stage II Mantle Cell Lymphoma
- Noncontiguous Stage II Mantle Cell Lymphoma
- Stage I Mantle Cell Lymphoma
- Stage III Mantle Cell Lymphoma
- Stage IV Mantle Cell Lymphoma

## Interventions

- **DRUG:** bortezomib
- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** vincristine
- **DRUG:** dexamethasone
- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** pegfilgrastim
- **PROCEDURE:** Autologous stem cell transplantation (ASCT)

## Key facts

- **NCT ID:** NCT00433537
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2014-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00433537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00433537, "Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00433537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*